Savara Inc.

SVRA

HealthcareSmall CapUS Equities · NYSE / NASDAQ

AI Agents

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Valuation

Market Cap$1.1B

Current Price$5.80as of Jun 23, 2026

P/E Ratio-9.14

P/B Ratio5.35

EV / EBITDA-8.83

EV / Sales-

Profitability

Operating Margin-

Net Profit Margin-

EBITDA Margin-

Returns

ROE-58.5%

ROCE-52.7%

ROIC %-48.5%

ROA-46.9%

Solvency

Current Ratio11.85

Debt / Equity0.15

Debt / Assets0.12

CFO / Net Profit0.85

Price History▲ 168.75% over 1Y

Technical Chart

Historical Performance Charts

5-year financial trends. Figures in USD millions.

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

No margin data.

Growth Summary

Latest fiscal year: 2025

Revenue$0M

EBITDA$-123M▲ 20.0%

Net Profit$-119M▲ 23.9%

Cash from Ops (CFO)$-101M▲ 13.4%

Free Cash Flow (FCF)$-101M▲ 13.4%

Revenue CAGR 3Y-

Revenue CAGR 5Y-

Net Profit CAGR 3Y-

Net Profit CAGR 5Y-

Historical Growth

Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)

Year	Revenue	EBITDA	Net Profit	FCF	ROE	Rev Growth 1Y	NP Growth 1Y
2025	$0M	$-123M	$-119M	$-101M	-58.5%	-	23.9%
2024	$0M	$-102M	$-96M	$-89M	-55.9%	-	75.3%
2023	$0M	$-59M	$-55M	$-51M	-39.0%	-	43.4%
2022	$0M	$-38M	$-38M	$-35M	-35.4%	-	-
2021	-	-	-	-	-

Financial Statements

Income statement, balance sheet, and cash flow as reported

Consolidated Figures in USD Millions.

Metric	2021	2022	2023	2024	2025
Total Revenue	-	0	0	0	0
Operating Revenue	-	0	0	0	0
Operating Expense	-	38.04	59.21	102.40	122.76
Research And Development	-	27.88	44.26	78.03	81.40
Selling General And Administration	-	10.93	15.67	25.04	42.06
Total Expenses	-	38.04	59.21	102.40	122.76
Operating Income	-	-38.04	-59.21	-102.40	-122.76
Total Operating Income As Reported	-	-38.84	-60.01	-103.20	-123.55
EBITDA	-	-37.88	-59.13	-102.27	-122.68
Normalized EBITDA	-	-37.86	-59.21	-102.32	-122.44
EBIT	-	-38.04	-59.21	-102.40	-122.76
Interest Income	-	-	4.44	6.47	4.16
Interest Expense	2.28	0.09	-	-	-
Net Interest Income	-	-0.09	4.44	6.47	4.16
Other Income Expense	-	-0.02	0.08	0.05	-0.24
Interest Income Non Operating	-	-	4.44	6.47	4.16
Interest Expense Non Operating	2.28	0.09	-	-	-
Net Non Operating Interest Income Expense	-	-0.09	4.44	6.47	4.16
Pretax Income	-	-38.15	-54.70	-95.88	-118.84
Tax Rate For Calcs	-	0	0	0	0
Tax Effect Of Unusual Items	-	0	0	0	0
Net Income Continuous Operations	-	-38.15	-54.70	-95.88	-118.84
Net Income From Continuing And Discontinued Operation	-	-38.15	-54.70	-95.88	-118.84
Net Income From Continuing Operation Net Minority Interest	-	-38.15	-54.70	-95.88	-118.84
Net Income	-	-38.15	-54.70	-95.88	-118.84
Net Income Common Stockholders	-	-38.15	-54.70	-95.88	-118.84
Net Income Including Noncontrolling Interests	-	-38.15	-54.70	-95.88	-118.84
Normalized Income	-	-38.13	-54.77	-95.93	-118.60
Diluted NI Availto Com Stockholders	-	-38.15	-54.70	-95.88	-118.84
Basic Average Shares	-	152.77	165.20	198.19	222.39
Diluted Average Shares	-	152.77	165.20	198.19	222.39
Reconciled Depreciation	-	0.17	0.08	0.13	0.09
Total Unusual Items	-	-0.02	0.08	0.05	-0.24
Total Unusual Items Excluding Goodwill	-	-0.02	0.08	0.05	-0.24
Special Income Charges	-	-	-	0	-0.55
Other Special Charges	-	-	-	-	0.55
Gain On Sale Of Security	-	-0.02	0.08	0.05	0.31
Depreciation Amortization Depletion Income Statement	-	0.03	0.08	0.13	0.09
Depreciation And Amortization In Income Statement	-	0.03	0.08	0.13	0.09
General And Administrative Expense	-	10.93	15.67	25.04	42.06
Other Gand A	-	10.93	15.67	25.04	42.06
Total Other Finance Cost	-	0.09	-4.44	-	-
Other Taxes	-	-0.80	-0.80	-0.80	-0.78

Peer Comparison

Healthcare sector peers, ranked by market cap

Company	Ticker	Market Cap	P/E	P/B	ROE	EV/EBITDA
Savara Inc.this co.	SVRA	$1.1B	-9.14	5.35	-58.5%	-8.83
OPKO Health, Inc.	OPK	$1.1B	-4.88	0.87	-17.8%	-27.38
Aktis Oncology, Inc.	AKTS	$1.1B	-17.25	-7.52	43.6%	-14.83
MannKind Corporation	MNKD	$1.1B	185.49	-21.31	-11.5%	26.79
Omada Health, Inc.	OMDA	$1.1B	-84.72	4.71

Learn while you research

Hand-picked academy chapters to deepen your understanding of Savara Inc. and the metrics that matter.

01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read 02 Stock Market Risks

Loading…

Year

Revenue

EBITDA

Net Profit

FCF

ROE

Rev Growth 1Y

NP Growth 1Y

2025

$0M

$-123M

$-119M

$-101M

-58.5%

23.9%

2024

$0M

$-102M

$-96M

$-89M

-55.9%

75.3%

2023

$0M

$-59M

$-55M

$-51M

-39.0%

43.4%

2022

$0M

$-38M

$-35M

-35.4%

2021

Metric

2021

2022

2023

2024

2025

Total Revenue

Operating Revenue

Operating Expense

38.04

59.21

102.40

122.76

Research And Development

27.88

44.26

78.03

81.40

Selling General And Administration

10.93

15.67

25.04

42.06

Total Expenses

38.04

59.21

102.40

122.76

Operating Income

-38.04

-59.21

-102.40

-122.76

Total Operating Income As Reported

-38.84

-60.01

-103.20

-123.55

EBITDA

-37.88

-59.13

-102.27

-122.68

Normalized EBITDA

-37.86

-59.21

-102.32

-122.44

EBIT

-38.04

-59.21

-102.40

-122.76

Interest Income

4.44

6.47

4.16

Interest Expense

2.28

0.09

Net Interest Income

-0.09

4.44

6.47

4.16

Other Income Expense

-0.02

0.08

0.05

-0.24

Interest Income Non Operating

4.44

6.47

4.16

Interest Expense Non Operating

2.28

0.09

Net Non Operating Interest Income Expense

-0.09

4.44

6.47

4.16

Pretax Income

-38.15

-54.70

-95.88

-118.84

Tax Rate For Calcs

Tax Effect Of Unusual Items

Net Income Continuous Operations

-38.15

-54.70

-95.88

-118.84

Net Income From Continuing And Discontinued Operation

-38.15

-54.70

-95.88

-118.84

Net Income From Continuing Operation Net Minority Interest

-38.15

-54.70

-95.88

-118.84

Net Income

-38.15

-54.70

-95.88

-118.84

Net Income Common Stockholders

-38.15

-54.70

-95.88

-118.84

Net Income Including Noncontrolling Interests

-38.15

-54.70

-95.88

-118.84

Normalized Income

-38.13

-54.77

-95.93

-118.60

Diluted NI Availto Com Stockholders

-38.15

-54.70

-95.88

-118.84

Basic Average Shares

152.77

165.20

198.19

222.39

Diluted Average Shares

152.77

165.20

198.19

222.39

Reconciled Depreciation

0.17

0.08

0.13

0.09

Total Unusual Items

-0.02

0.08

0.05

-0.24

Total Unusual Items Excluding Goodwill

-0.02

0.08

0.05

-0.24

Special Income Charges

-0.55

Other Special Charges

0.55

Gain On Sale Of Security

-0.02

0.08

0.05

0.31

Depreciation Amortization Depletion Income Statement

0.03

0.08

0.13

0.09

Depreciation And Amortization In Income Statement

0.03

0.08

0.13

0.09

General And Administrative Expense

10.93

15.67

25.04

42.06

Other Gand A

10.93

15.67

25.04

42.06

Total Other Finance Cost

0.09

-4.44

Other Taxes

-0.80

-0.78

Company

Ticker

Market Cap

P/E

P/B

ROE

EV/EBITDA

Savara Inc.this co.

SVRA

$1.1B

-9.14

5.35

-58.5%

-8.83

OPKO Health, Inc.

OPK

$1.1B

-4.88

0.87

-17.8%

-27.38

Aktis Oncology, Inc.

AKTS

$1.1B

-17.25

-7.52

43.6%

-14.83

MannKind Corporation

MNKD

$1.1B

185.49

-21.31

-11.5%

26.79

Omada Health, Inc.

OMDA

$1.1B

-84.72

4.71

Savara Inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

Savara Inc.

Valuation

Profitability

Returns

Solvency

Historical Performance Charts

Revenue vs Net Profit (5Y)

Free Cash Flow vs Operating Cash Flow (5Y)

Operating Margin % (5Y)

Growth Summary

Historical Growth

Financial Statements

Peer Comparison

Key concepts to brush up on